Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TAK) is a Japan-headquartered, research-led pharmaceutical group that develops, manufactures and markets prescription medicines globally. Its portfolio spans oncology, gastroenterology, rare diseases and neuroscience, and the company combines internal R&D with selective acquisitions to broaden its pipeline. With a market capitalisation of around $44.97 billion, Takeda is sizeable but faces the typical dynamics of large biopharma: high R&D spend, regulatory review cycles, patent expiries and pricing pressures in major markets. Investors should weigh potential upside from successful drug launches and pipeline progression against clinical trial risk, competition and currency exposure. Takeda's strategic focus on specialty medicines and efficiency programmes may support long-term margins, yet returns are uncertain and can fluctuate. This summary is for general, educational purposes only and not personal investment advice; investors should consider their financial circumstances and seek independent advice before acting.
Why It's Moving
Takeda edges higher amid analyst buy ratings signaling 22% upside potential.
Takeda's shares ticked up 0.2% on December 11 as analysts unanimously recommend buying, eyeing a $17.40 target that implies robust growth prospects despite a recent revenue dip. Robust free cash flow and a juicy 4.65% dividend yield are bolstering investor confidence in the pharma giant's strategic positioning.
- Analysts project 21.71% upside to $17.40 average target, backed by three buy ratings and no sells, reflecting faith in Takeda's navigation of pharma headwinds[1].
- Free cash flow hits $748.5 billion, offering firepower for investments or deals even as revenue growth slipped 5.4%, underscoring financial resilience[1].
- Stock trading just above 50-day moving average with neutral RSI at 43.64, hinting at building momentum without overbought risks[1].
Takeda edges higher amid analyst buy ratings signaling 22% upside potential.
Takeda's shares ticked up 0.2% on December 11 as analysts unanimously recommend buying, eyeing a $17.40 target that implies robust growth prospects despite a recent revenue dip. Robust free cash flow and a juicy 4.65% dividend yield are bolstering investor confidence in the pharma giant's strategic positioning.
- Analysts project 21.71% upside to $17.40 average target, backed by three buy ratings and no sells, reflecting faith in Takeda's navigation of pharma headwinds[1].
- Free cash flow hits $748.5 billion, offering firepower for investments or deals even as revenue growth slipped 5.4%, underscoring financial resilience[1].
- Stock trading just above 50-day moving average with neutral RSI at 43.64, hinting at building momentum without overbought risks[1].
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Takeda's stock due to its potential to reach a higher price.
Financial Health
Takeda Pharmaceutical Company is performing well with strong revenue, cash flow, and profit margins.
Dividend
Takeda's projected dividend yield of 1.28% is lower than many investors prefer. If you invested $1000 you would be paid $12.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TAK
The Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketJapanese Stocks
Dive into the unique blend of industrial power and technological innovation that defines Japan's market leaders. These carefully selected companies represent the best of Japan's globally respected brands, offering you exposure to the world's third-largest economy.
Published: June 17, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
R&D-led pipeline
Takeda's investment in research can drive long-term growth if trials succeed, though clinical setbacks can also weigh on performance.
Global market exposure
Broad geographic reach diversifies revenue sources but adds currency and regulatory complexity that investors should monitor.
M&A and strategy
Strategic acquisitions can expand the pipeline and scale, yet integration and debt impacts are important considerations for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
